Correspondence 0000950170-23-064498 from aTYR PHARMA INC (ATYR)
aTYR PHARMA INC
Date: Nov. 16, 2023 · CIK: 0001339970 · Accession: 0000950170-23-064498
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-275455
Letter
aTyr Pharma, Inc.
10240 Sorrento Valley Road, Suite 300
San Diego, CA, 92121
November 16, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Daniel Crawford
Re: aTyr Pharma, Inc.
Registration Statement on Form S-3 (File No. 333-275455)
Request for Acceleration of Effective Date
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, aTyr Pharma, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) and declare the Registration Statement effective as of 4:00 p.m. Eastern time, on November 20, 2023, or as soon thereafter as possible, or at such other time as the Company or its legal counsel, Cooley LLP, may request by telephone to the staff of the Commission. The Company hereby authorizes each of Charles J. Bair and Katherine Denby of Cooley LLP to make such a request on its behalf.
Once the Registration Statement has been declared effective, please orally confirm that event with Katherine Denby of Cooley LLP at (202) 776-2070 or kdenby@cooley.com.
Sincerely,
aTyr Pharma, Inc.
Show Raw Text
CORRESP
1
filename1.htm
CORRESP
aTyr Pharma, Inc.
10240 Sorrento Valley Road, Suite 300
San Diego, CA, 92121
November 16, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Daniel Crawford
Re: aTyr Pharma, Inc.
Registration Statement on Form S-3 (File No. 333-275455)
Request for Acceleration of Effective Date
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, aTyr Pharma, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) and declare the Registration Statement effective as of 4:00 p.m. Eastern time, on November 20, 2023, or as soon thereafter as possible, or at such other time as the Company or its legal counsel, Cooley LLP, may request by telephone to the staff of the Commission. The Company hereby authorizes each of Charles J. Bair and Katherine Denby of Cooley LLP to make such a request on its behalf.
Once the Registration Statement has been declared effective, please orally confirm that event with Katherine Denby of Cooley LLP at (202) 776-2070 or kdenby@cooley.com.
Sincerely,
aTyr Pharma, Inc.
By:
/s/ Jill Broadfoot
Jill Broadfoot
Chief Financial Officer